secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001104659-25-045598
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode receives Nasdaq delisting notice; plans to appeal bid-price deficiency
--------------------------------------------------------------------------------

- Company received Nasdaq notice on May 6, 2025 for failing to maintain $1.00 minimum bid price for 30 consecutive days (Mar 24–May 5).
- Due to multiple reverse stock splits over prior two years (cumulative ratio >=250:1), Company is ineligible for standard compliance period; must appeal by May 13, 2025.
- TransCode plans to timely request a hearing before a Nasdaq Hearings Panel; delisting stayed pending hearing outcome.
- No assurance the Company will ultimately regain compliance or remain listed on Nasdaq.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465925045598/0001104659-25-045598-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465925045598/tm2514386d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-045598

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer